secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001628280-25-013085
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo FY2024 net loss $97.9M; FDA clears ST-503 IND; Fabry BLA path to Accelerated Approval
--------------------------------------------------------------------------------

- FY2024 net loss $97.9M ($0.49/share) vs $257.8M ($1.48) in 2023; revenue $57.8M vs $176.2M.
- Cash $41.9M at Dec 31, 2024; with $10.1M ATM proceeds and $5M Pfizer payment, funds operations into mid-Q2 2025.
- FDA cleared IND for ST-503 (chronic neuropathic pain); patient enrollment expected mid-2025; preliminary efficacy data Q4 2026.
- FDA agreed to Accelerated Approval for isaralgagene civaparvovec in Fabry using Phase 1/2 data; BLA submission H2 2025.
- License agreements with Genentech (Aug 2024) and Astellas (Dec 2024) for STAC-BBB capsid; $20M upfront from Astellas.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828025013085/0001628280-25-013085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828025013085/sgmo-20250317.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-013085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer